Glycopeptide Antibiotics Market Report 2026

Glycopeptide Antibiotics Market Overview

• Glycopeptide Antibiotics market size has reached to $3.78 billion in 2025 • Expected to grow to $5.89 billion in 2030 at a compound annual growth rate (CAGR) of 9.3% • Growth Driver: Combatting Gram-Positive Threat The Surging Demand For Glycopeptide Antibiotics In Response To Rising Infection Rates • Market Trend: Biosynthetic Innovation In Glycopeptide Scaffolds • North America was the largest region in 2025.

What Is Covered Under Glycopeptide Antibiotics Market?

Glycopeptide antibiotics are a group of antibiotics having structures that either comprise a glycosylated cyclic or polycyclic non-ribosomal peptide, used to inhibit bacterial cell wall formation. They were first discovered from plant and soil bacteria. The main drugs of glycopeptide antibiotics are vancomycin, dalbavancin, oritavancin, and others. Vancomycin belongs to a family of drugs known as glycopeptide antibiotics that eliminates microorganisms in the intestines and is used to treat colitis, which can develop after antibiotic therapy. These are administered through oral, parenteral, and other routes for the treatment of skin and structure infection, meningitis, clostridioides difficile infection, enterocolitis, and other indications by hospitals, specialty clinics, home care, and other end-users.

What Is The Glycopeptide Antibiotics Market Growth Forecast?

The glycopeptide antibiotics market size is expected to see strong growth in the next few years. It will grow to $5.89 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to growth in multidrug-resistant pathogens, increasing adoption of long-acting glycopeptides, rising demand for outpatient and home-based antibiotic therapy, continued r&d in next-generation glycopeptides, growing global healthcare expenditure. Major trends in the forecast period include rising dependence on glycopeptides for resistant infections, expansion of lipoglycopeptide antibiotics portfolio, increased hospital use of intravenous glycopeptides, growing focus on optimized dosing and therapeutic monitoring, wider adoption in severe gram-positive infections.

What Is The Driver Of The Glycopeptide Antibiotics Market?

The increasing prevalence of gram-positive infections is expected to propel the growth of the glycopeptide antibiotic market in the coming years. Gram-positive infections are infections caused by gram-positive bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, and others. Glycopeptide antibiotics are effective against many gram-positive bacteria due to their unique mode of action, which targets bacterial cell wall formation. For instance, in June 2023, according to the Group A Streptococcal Infections: Report on Seasonal Activity in England 2022–2023 by the UK Health Security Agency, a UK-based government body responsible for public health and infectious-disease protection, invasive Group A Streptococcus (iGAS) activity rose sharply, with 509 laboratory-confirmed iGAS notifications reported by week 46 of 2023, including a weekly peak of 73 cases. This escalation underscores increasing infectious-disease burden and intensifies demand for effective antimicrobial therapies across the healthcare system. Therefore, the increasing prevalence of gram-positive infections is driving the glycopeptide antibiotic industry.

Key Players In The Global Glycopeptide Antibiotics Market

Major companies operating in the glycopeptide antibiotics market are ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Cumberland Pharmaceuticals Inc., Janssen Global, Bristol-Myers Squibb Company, Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Alvogen, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc.

Global Glycopeptide Antibiotics Market Trends and Insights

Major companies operating in the glycopeptide antibiotics market are focusing on developing innovative products, such as novel glycopeptide scaffolds, to gain a competitive advantage. Novel glycopeptide scaffolds represent structurally distinct antibiotic backbones, derived via advanced biosynthetic or natural-product mining techniques. For instance, in May 2025, a Chinese-European research consortium, a China-based cross-continental expertise, introduced Saarvienin A, a newly discovered glycopeptide featuring a halogenated peptide core, an unusual ureido linkage, and five distinct sugar or aminosugar units. Saarvienin A does not bind the traditional cell-wall target of other glycopeptides, indicating a potentially novel mechanism, and exhibits potent in vitro activity against resistant Gram-positive pathogens such as MRSA and vancomycin-resistant Enterococcus. While this innovation signals a major step forward in addressing antibiotic resistance, it faces challenges including clinical translation, optimization for safety, and scale-up of production.

What Are Latest Mergers And Acquisitions In The Glycopeptide Antibiotics Market?

In January 2023, Fairlong Capital LLC, a US-based investment company, acquired DoseMeRx for an undisclosed amount. Through this acquisition, Fairlong Capital aims to enhance its precision dosing capabilities and improve patient outcomes with advanced medication management solutions. This strategic move positions the company to leverage innovative technology for more effective healthcare delivery. DoseMeRx, a US-based Bayesian dosing platform, optimizes dosing for glycopeptide antibiotics, such as vancomycin, by personalizing treatment based on patient-specific factors

What Defines the Glycopeptide Antibiotics Market?

The glycopeptide antibiotics market consists of sales of teicoplanin, telavancin and ramoplanin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Glycopeptide Antibiotics Market Report 2026?

The glycopeptide antibiotics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the glycopeptide antibiotics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.